Analysis MediGene AG (MDGEF)
6/4/2024
Analysis of MediGene AG (MDGEF)
MediGene AG (MDGEF) has been showing a stable price close around 2.23807 in the past few days. The Relative Strength Index (RSI) indicator is around 49.58, indicating a neutral position. The Moving Average Convergence Divergence (MACD) indicator has been fluctuating around 0, suggesting a balance between the short-term and long-term trends.The Simple Moving Average (SMA) and Exponential Moving Average (EMA) are close to the current price, indicating a stable trend. However, the Weighted Moving Average (WMA) is slightly higher, suggesting some recent price fluctuations.
Overall, based on the indicators and moving averages, MediGene AG seems to be in a consolidation phase with no clear trend direction. Traders and investors may need to wait for a clearer signal before making any significant trading decisions.
Cash Flow 💶
This is a cash flow statement. Here are some conclusions we can draw from the data:1. The company's free cash flow has been fluctuating over the years, with the highest value in 2022 and the lowest in 2020.
2. Operating cash flow has generally been increasing, indicating improved operational efficiency.
3. The company has been consistently paying interest and income taxes, with varying amounts each year.
4. The end cash position has also been fluctuating, reaching its highest value in 2020.
5. Financing activities show significant changes each year, with fluctuations in common dividends, stock repurchases, and debt issuances.
6. Investing activities also vary, with changes in acquisitions, investments, and capital expenditures.
7. Overall, the company's financial performance seems to be stable, with some fluctuations in key financial metrics over the years.
Earnings estimate
Based on the analysts' estimates for future quarterly and annual earnings per share:1. For the current quarter ending on June 30, 2024, the average estimated EPS is $1.23, with a low estimate of $1.18 and a high estimate of $1.26. This shows an improvement compared to the EPS of $1.17 from the same quarter a year ago.
2. For the next quarter ending on September 30, 2024, the average estimated EPS is $1.42, with a low estimate of $1.33 and a high estimate of $1.51. This also indicates growth from the EPS of $1.35 in the same quarter last year.
3. Looking at the estimates for the current fiscal year ending on September 30, 2024, the average estimated EPS is $6.10, ranging from a low estimate of $5.95 to a high estimate of $6.41. This reflects an increase from the EPS of $5.67 for the previous fiscal year.
4. For the next fiscal year ending on September 30, 2025, the average estimated EPS is $6.69, with a low estimate of $5.92 and a high estimate of $7.31. This suggests a growth trajectory from the EPS of $6.10 in the current fiscal year.
Overall, the analysts' estimates point towards a positive outlook for the company's earnings per share, showing a trend of improvement and growth in the upcoming quarters and years.
Revenue estimate
Based on the analysts' estimates for the future quarterly and annual sales of the company, we can draw the following conclusions:1. For the current quarter ending on June 30, 2024, the average sales estimate is $77,545,400,000, with a sales growth of 2% compared to the same quarter last year. The number of analysts providing estimates is 25.
2. For the next quarter ending on September 30, 2024, the average sales estimate is $85,501,800,000, showing a sales growth of 3% from the previous year. The number of analysts providing estimates remains at 25.
3. For the current fiscal year ending on September 30, 2024, the average sales estimate is $357,772,000,000, with a sales growth of 1% compared to the previous fiscal year. The number of analysts providing estimates increases to 38.
4. Looking ahead to the next fiscal year ending on September 30, 2025, the average sales estimate is $380,772,000,000, indicating a significant sales growth of 6% from the current fiscal year. The number of analysts providing estimates remains at 38.
Overall, the analysts are forecasting moderate to strong sales growth for both the upcoming quarters and the next fiscal year, with an increasing number of analysts providing estimates for the company's performance.
Growth estimates
Based on the consensus estimates provided by analysts, we can draw the following conclusions regarding the growth rate of the company for different periods:1. Current Quarter: The estimated growth rate for the current quarter is 5.1%.
2. Next Quarter: The estimated growth rate for the next quarter is 5.2%.
3. Current Year: The estimated growth rate for the current year is 7.6%.
4. Next Year: The estimated growth rate for the next year is 9.7%.
5. Past 5 Years (per annum): The average annual growth rate for the past 5 years is 20.1%.
6. Next 5 Years (per annum): The estimated average annual growth rate for the next 5 years is 9.7%.
These estimates suggest a positive growth trend for the company, with a significant decrease in growth rate compared to the past 5 years but still a healthy growth rate expected for the upcoming periods.
Price target
The analysts' forecast for the future price of the security is as follows:- Low: $164
- High: $275
- Median: $201.43
- Average: $204.58
- Current price: $192.25
Based on these forecasts, it appears that the analysts are generally optimistic about the future price of the security, with a median forecast above the current price. The range between the low and high forecasts is quite wide, indicating some uncertainty or differing opinions among analysts.
Earnings
The company's results for the most recent quarter ending on April 30, 2025, have not been provided at this time. The previous results were reported on February 27, 2025, through the Transfer Agent. Before that, on January 31, 2025, the results were released after hours. The results for October 31, 2024, were not provided at the time. On August 1, 2024, the company reported an earnings per share (EPS) estimate of 1.32.Main Statystic ðŸ§
The data provided includes financials, stock statistics, valuation metrics, stock price summary, and dividends and splits information for a specific company.In terms of financials, the company has strong operating cash flow and levered free cash flow, with a healthy balance sheet showing a current ratio slightly above 1. The profit margin and operating margin are also favorable, indicating efficient operations. The company's fiscal year ends in September 2023, and the most recent quarter reported is March 2024. The company shows good returns on assets and equity.
Looking at stock statistics, the company has a low short ratio and a significant percentage of shares held by institutions. The stock price summary reveals volatility in the stock's performance over the past year.
Valuation metrics show a relatively high PEG ratio and forward PE ratio, with the company's market capitalization and enterprise value also provided. The price to book ratio and price to sales ratio are on the higher side, indicating potentially overvalued stock.
Lastly, dividends and splits information show the company's dividend dates, payout ratio, and historical dividend yields. The company has a history of dividend payments and stock splits.
Income statement 💸
These are the revenue figures. Here are the conclusions:1. The company's sales revenue has been increasing steadily over the years, from $274.5 billion in 2020 to $383.3 billion in 2023.
2. Despite the increase in sales, the cost of goods sold has also been rising, indicating a potential challenge in managing production or procurement costs.
3. The gross profit margin has remained relatively stable, with a slight decrease in 2023 compared to previous years.
4. Operating income has shown a positive trend, reaching $114.3 billion in 2023 from $66.3 billion in 2020.
5. Net income has also been increasing consistently, reflecting the company's ability to manage its expenses and generate profits.
6. Earnings per share (EPS) have shown a slight fluctuation but have generally been on an upward trajectory.
7. The company has been able to maintain a healthy EBITDA margin, indicating efficient operational performance.
8. Overall, the financial performance of the company in terms of revenue and profitability has been positive and improving over the years.
Balance Sheet
These are balance sheets. Here are the conclusions:1. The total assets have been increasing over the years, reaching $365,725,000,000 in 2018.
2. Current assets include cash, inventory, and receivables, with a significant portion in cash and cash equivalents.
3. Non-current assets consist of investments, machinery, and other assets.
4. Total liabilities have also been increasing, but at a slower pace compared to assets.
5. Shareholders' equity has shown an overall positive trend, indicating a healthy financial position.
6. The company has been investing in non-current assets such as machinery, equipment, and investments.
7. There is a consistent mix of short-term and long-term liabilities to support the asset base.
8. Retained earnings have been fluctuating but have shown an overall positive trend.
9. The company has been managing its cash position well, with a significant amount in cash and cash equivalents.
10. Overall, the financial health of the company seems stable and improving over the years.
MACD of MDGEF
This is not investment advice. Remember to verify the information provided here.
Get access to the full analysis
- Over 35 000 indexes
- CFD, Forex, Crypto and Stocks Exchange
- Over 150 Indicators
- Pattern and candle analysis
- Support and resistance levels
- Fundamental, technical and sentimental analysis
- Power from AI
